Bank of America
IMVT icon

Bank of America’s Immunovant IMVT Stock Holding History

Bank of America’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,800
Closed -$123K – 8313
2024
Q1 		$123K Hold
3,800
– – ﹤0.01% 6145
2023
Q4 		$160K Buy
+3,800
New +$140K ﹤0.01% 6192

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bank of America's IMVT Position: Q1 2026 in Review

Bank of America increased its Immunovant (IMVT) stake by 185% in Q1 2026, buying an estimated $15M and bringing the position to 893,678 shares worth $22.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2289.

Bank of America first reported a position in IMVT in Q1 2020 and has held it in 25 quarters since. The position peaked at $23.1M in Q3 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Bank of America held 893,678 shares of Immunovant worth $22.2M as of Q1 2026.
  • Bank of America bought 580,197 Immunovant shares in Q1 2026, an estimated $15M.
  • Immunovant made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2289 holding.
  • Bank of America first reported a position in Immunovant in Q1 2020 and has held it in 25 quarters since.
  • Bank of America's Immunovant position peaked at $23.1M in Q3 2023.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.